

Table S8: BAMA paired response magnitude testing between day 14 and day 70 by group. Testing was done using the Wilcoxon signed-rank test (two-sided, $\alpha = 0.05$) and p-values less than 0.05 are highlighted. Testing included all participants for which data was available at days 14 and 70. Median, minimum, and maximum response magnitude values are presented by treatment group and time point.

Comparison: Day 14 vs. Day 70				
Antigen	Treatment	Pairs	Median (Min., Max.)	P-value
eOD-GT8 60mer	DPBS sucrose	12	115.77 [19.75, 1475.18] vs. 104.16 [7.67, 1758.87]	0.3394
	20 µg eOD-GT8 60mer + AS01B	17	35602.21 [22360.05, 55150.59] vs. 73433.96 [70562.94, 76603.27]	<0.0001
	100 µg eOD-GT8 60mer + AS01B	17	34527.28 [12027.79, 45799.40] vs. 70028.67 [59742.36, 73011.17]	<0.0001
eOD-GT8 monomer	DPBS sucrose	12	2.65 [0.00, 7.95] vs. 3.60 [0.00, 13.49]	1.0000
	20 µg eOD-GT8 60mer + AS01B	17	7134.74 [2088.03, 25927.21] vs. 60151.79 [54249.33, 66788.59]	<0.0001
	100 µg eOD-GT8 60mer + AS01B	16	4615.60 [191.61, 25353.21] vs. 56109.55 [46179.55, 63017.30]	<0.0001
eOD-GT8 KO11 monomer	DPBS sucrose	12	3.42 [0.00, 18.12] vs. 1.75 [0.00, 7.25]	0.0771
	20 µg eOD-GT8 60mer + AS01B	17	550.77 [167.96, 8660.76] vs. 55882.04 [47636.29, 59930.04]	<0.0001
	100 µg eOD-GT8 60mer + AS01B	17	332.27 [20.27, 7956.55] vs. 48405.77 [40832.43, 58612.13]	<0.0001
CD4bs	DPBS sucrose	12	-0.35 [-11.90, 2.01] vs. 1.18 [-3.06, 10.17]	0.1631
	20 µg eOD-GT8 60mer + AS01B	17	6413.49 [1527.28, 23898.38] vs. 4867.38 [3061.93, 9726.25]	0.1901
	100 µg eOD-GT8 60mer + AS01B	16	4254.89 [171.34, 17396.66] vs. 6975.37 [3455.27, 12095.50]	0.3484
Lumazine synthase	DPBS sucrose	12	3876.30 [125.69, 8481.65] vs. 4008.23 [161.85, 15033.45]	0.9097
	20 µg eOD-GT8 60mer + AS01B	17	14847.52 [4851.62, 33184.07] vs. 70287.38 [55685.72, 74489.50]	<0.0001
	100 µg eOD-GT8 60mer + AS01B	17	8831.92 [2848.56, 41963.97] vs. 66854.65 [59925.93, 70961.62]	<0.0001